Crossject (ALCJ) - Net Assets

Latest as of December 2025: €-4.87 Million EUR ≈ $-5.69 Million USD

Based on the latest financial reports, Crossject (ALCJ) has net assets worth €-4.87 Million EUR (≈ $-5.69 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€30.43 Million ≈ $35.58 Million USD) and total liabilities (€35.30 Million ≈ $41.27 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Crossject (ALCJ) total assets for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric Value
Current Net Assets €-4.87 Million
% of Total Assets -16.0%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change -177.47%
Growth Volatility 506.54

Crossject - Net Assets Trend (2010–2025)

This chart illustrates how Crossject's net assets have evolved over time, based on quarterly financial data. Check ALCJ intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Annual Net Assets for Crossject (2010–2025)

The table below shows the annual net assets of Crossject from 2010 to 2025. For live valuation and market cap data, see Crossject market capitalisation.

Year Net Assets Change
2025-12-31 €-4.87 Million
≈ $-5.69 Million
-82.12%
2024-12-31 €-2.67 Million
≈ $-3.13 Million
+49.27%
2023-12-31 €-5.27 Million
≈ $-6.16 Million
-296.17%
2022-12-31 €2.69 Million
≈ $3.14 Million
+149.01%
2021-12-31 €-5.48 Million
≈ $-6.41 Million
-384.99%
2020-12-31 €-1.13 Million
≈ $-1.32 Million
-137.50%
2019-12-31 €3.01 Million
≈ $3.52 Million
+82.16%
2018-12-31 €1.65 Million
≈ $1.93 Million
-72.81%
2017-12-31 €6.09 Million
≈ $7.11 Million
-3.15%
2016-12-31 €6.28 Million
≈ $7.35 Million
-28.57%
2015-12-31 €8.80 Million
≈ $10.29 Million
-39.26%
2014-12-31 €14.48 Million
≈ $16.93 Million
+1428.46%
2013-12-31 €947.65K
≈ $1.11 Million
+149.75%
2012-12-31 €-1.90 Million
≈ $-2.23 Million
+11.29%
2011-12-31 €-2.15 Million
≈ $-2.51 Million
+74.40%
2010-12-31 €-8.39 Million
≈ $-9.81 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Crossject's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 1051976100.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock €5.22 Million %
Other Comprehensive Income €892.00K %
Other Components €7.77 Million %
Total Equity €-4.87 Million 100.00%

Crossject Competitors by Market Cap

The table below lists competitors of Crossject ranked by their market capitalization.

Company Market Cap
CO2 Energy Transition Corp. Unit
NASDAQ:NOEMU
$93.41 Million
Cemacon Zalau
RO:CEON
$93.42 Million
Phoenix Group Holdings PLC
LSE:PHNX
$93.45 Million
Shinsegae Food
KO:031440
$93.47 Million
Nanjing Panda Electronics Company Limited
F:NNJ
$93.36 Million
TAT HONG EQ.SRV. DL-08
F:1Q2
$93.35 Million
Hurriyet Gazetecilik ve Matbaacilik AS
IS:HURGZ
$93.35 Million
CFSB Bancorp Inc
NASDAQ:CFSB
$93.32 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Crossject's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from -2,673,000 to -4,873,000, a change of -2,200,000.
  • Net loss of 10,367,000 reduced equity.
  • Share repurchases of 369,000 reduced equity.
  • New share issuances of 4,814,620 increased equity.
  • Other comprehensive income decreased equity by 79,999.
  • Other factors increased equity by 3,801,379.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income €-10.37 Million -212.74%
Share Repurchases €369.00K -7.57%
Share Issuances €4.81 Million +98.8%
Other Comprehensive Income €-80.00K -1.64%
Other Changes €3.80 Million +78.01%
Total Change €- %

Book Value vs Market Value Analysis

This analysis compares Crossject's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2010-12-31 €-1.89 €1.50 x
2011-12-31 €-0.48 €1.50 x
2012-12-31 €-0.43 €1.50 x
2013-12-31 €0.18 €1.50 x
2014-12-31 €2.18 €1.50 x
2015-12-31 €1.32 €1.50 x
2016-12-31 €0.86 €1.50 x
2017-12-31 €0.68 €1.50 x
2018-12-31 €0.12 €1.50 x
2019-12-31 €0.15 €1.50 x
2020-12-31 €-0.05 €1.50 x
2021-12-31 €-0.24 €1.50 x
2022-12-31 €0.06 €1.50 x
2023-12-31 €-0.14 €1.50 x
2024-12-31 €-0.06 €1.50 x
2025-12-31 €-0.09 €1.50 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Crossject utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is above the historical average (-122.22%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2010 0.00% -2058.76% 0.07x 0.00x €-3.28 Million
2011 0.00% 237.75% 0.22x 0.00x €1.76 Million
2012 0.00% -261.88% 0.14x 0.00x €-735.29K
2013 -192.33% -194.74% 0.17x 5.96x €-1.92 Million
2014 -29.94% -313.04% 0.08x 1.27x €-5.78 Million
2015 -64.64% -358.57% 0.11x 1.58x €-6.57 Million
2016 -106.03% -468.32% 0.10x 2.27x €-7.29 Million
2017 -125.06% -235.32% 0.18x 2.91x €-8.22 Million
2018 -647.41% -438.26% 0.12x 12.18x €-10.88 Million
2019 -238.02% -1434.74% 0.02x 8.13x €-7.48 Million
2020 0.00% -203.22% 0.14x 0.00x €-9.73 Million
2021 0.00% -1184.87% 0.03x 0.00x €-10.19 Million
2022 -552.05% -1169.50% 0.03x 16.26x €-11.36 Million
2023 0.00% -5957.24% 0.01x 0.00x €-8.11 Million
2024 0.00% -310.94% 0.13x 0.00x €-12.53 Million
2025 0.00% 0.00% 0.00x 0.00x €-9.88 Million

Industry Comparison

This section compares Crossject's net assets metrics with peer companies in the Medical Instruments & Supplies industry.

Industry Context

  • Industry: Medical Instruments & Supplies
  • Average net assets among peers: $5,110,449,684
  • Average return on equity (ROE) among peers: -27.62%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Crossject (ALCJ) €-4.87 Million 0.00% N/A $93.38 Million
I.Ceram SA (ALICR) $1.85 Million -41.63% 1.92x $155.73K
Safe Orthopaedics SA (ALSAF) $2.46 Million -200.49% 1.16x $135.60K
Spineway (ALSPW) $506.00K 0.00% 3.93x $4.57 Million
Amplitude Surgical SAS (AMPLI) $70.91 Million -20.02% 2.88x $299.85 Million
Sartorius Stedim Biotech SA (DIM) $365.07 Million 10.55% 0.80x $15.98 Billion
EssilorLuxottica S. A. (EL) $35.33 Billion 3.05% 0.49x $88.81 Billion
Bonyf NV (MLBON) $345.47K 55.19% 3.01x $1.71 Million

About Crossject

PA:ALCJ France Medical Instruments & Supplies
Market Cap
$93.38 Million
€79.87 Million EUR
Market Cap Rank
#19378 Global
#293 in France
Share Price
€1.50
Change (1 day)
+0.00%
52-Week Range
€1.40 - €2.69
All Time High
€10.40
About

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster he… Read more